Clinical studies validate in vitro diagnostic test

Lophius Biosciences has announced the publication of two peer-reviewed scientific papers that validate its CE-marked in vitro diagnostic test, T-Track CMV.

The papers, published in BMC Immunology, demonstrate the test’s ability to measure human cytomegalovirus (CMV) specific cell-mediated immune response. Additionally, the T-Track CMV was shown to be able to identify candidate transplant recipients potentially at increased risk of CMV-related complications.

“The recent publications clearly demonstrate the technical capabilities of our assay T-Track CMV and give an outlook toward its ability to support personalised CMV therapy management,” commented Bernd Merkl, CEO and marketing director of Lophius Biosciences. “We are looking forward to the results of on-going clinical studies in allogenic hematopoietic stem cell and solid-organ transplant recipients to confirm the full clinical potential and the health-economic benefit of our test.”